REG - BATM Advanced Comm - Appointment of Non-Executive Director

Batm Advanced CommunicationsAnnouncement

13/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220413:nRSM1871Ia&default-theme=true

RNS Number : 1871I  BATM Advanced Communications Ld  13 April 2022

LEI: 213800FLQUB9J289RU66

13 April 2022

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Appointment of Non-Executive Director

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for
networking solutions and medical laboratory systems, is pleased to announce
the appointment of Dr. Avigdor Shafferman as a Non-Executive Director of the
Company with immediate effect.

 

Dr. Avigdor Shafferman, aged 75, had an established career at the Israel
Institute for Biological Research, a leading governmental applied research
institute specialising in the fields of biology, medicinal chemistry and
environmental sciences, where he worked for almost 40 years. Most recently,
from 1995 until his retirement in 2013, he was General Director of the
organistion. Other roles have included serving as a visiting professor in the
University of California, San Diego at the biology department as well as a
visiting senior research scientist at various leading research institutions in
the United States in various medical areas, including vaccines. Dr. Shafferman
holds a Ph.D. in physical chemistry from the Hebrew University of Jerusalem.

 

Previously, Dr. Shafferman served as an external director of the Group (as
defined under Israeli law) from February 2015 to February 2018. External
directors under Israeli law are appointed for terms of three years. With his
new appointment as a Non-executive Director, Dr. Shafferman will be subject to
annual re-election at the Group's annual general meeting.

 

Dr. Gideon Chitayat, Chairman of BATM, said: "On behalf of the Board, I would
like to welcome Avigdor back to BATM. He made an excellent contribution to our
business previously and we look forward to once again being able to leverage
his wealth of knowledge and experience as we continue to advance our
leading-edge medical diagnostics solutions."

 

There is no further information required to be disclosed in relation to Dr.
Shafferman pursuant to Listing Rule 9.6.13 and Dr. Shafferman does not have
any beneficial interest in BATM's ordinary shares.

 

 

Enquiries:

 BATM Advanced Communications
 Dr Zvi Marom, Chief Executive Officer                          +972 9866 2525
 Moti Nagar, Chief Financial Officer

 Shore Capital
 Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)  +44 20 7408 4050

 Luther Pendragon
 Harry Chathli, Claire Norbury                                  +44 20 7618 9100

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABRGDSBUBDGDD